51 results
10-Q
2021 Q2
VERV
Verve Therapeutics Inc
12 Aug 21
Quarterly report
8:53am
, except share and per share amounts)
(unaudited)
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss … inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties
8-K
EX-99.1
hea3qqur 5ou1
8 May 24
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
7:15am
S-1/A
3tp5oh6mgbkkx
14 Jun 21
IPO registration (amended)
6:15am
S-1
751qt5l51 i34qphhel
28 May 21
IPO registration
4:04pm
10-K
70j2vsf47nrtmuw
14 Mar 22
Annual report
7:04am
424B4
t8qh8e7nv3frda0 9tn
17 Jun 21
Prospectus supplement with pricing info
4:50pm
8-K
EX-99.1
6wnf3p xya5
12 Aug 21
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
8:20am
8-K
EX-99.1
5qpsvh4
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am
DRS
3qiip8pev6hkg7v5f
16 Apr 21
Draft registration statement
12:00am